IP Library Granted Patent US 7,498,426
Granted Patent B2
US 7,498,426 · App. 11/234,074 · Granted Mar 3, 2009

Immunostimulatory oligonucleotide multimers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,498,426
App. No.
11/234,074
Granted
Mar 3, 2009
Kind
B2
Abstract

The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.

Claims (7)

1. An immunostimulatory oligonucleotide having the structure 5′-CTGTCoG 2 TTCTC-X-CTCTTG 2 oCTGTC-5′; wherein X is a glycerol linker, o is phosphodiester linkage and G 2 is arabinoguanosine.

2. A composition comprising the oligonucleotide according to claim 1 and a physiologically acceptable carrier.

3. A method for generating an immune response in a vertebrate, the method comprising administering to the vertebrate an immunostimulatory oligonucleotide having the structure 5′-CTGTCoG 2 TTCTC-X-CTCTTG 2 oCTGTC-5′; wherein X is a glycerol linker, o is phosphodiester linkage and G 2 is arabinoguanosine.

4. The method according to claim 3 , wherein the route of administration is selected from parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop and mouthwash.

5. The oligonucleotide according to claim 1 , further comprising an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant.

6. The composition according to claim 2 , further comprising an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant.

7. The method according to claim 3 , further comprising administering an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Nov 30, 2005
From: HYBRIDON, INC
To: IDERA PHARMACEUTICALS, INC
Reel/Frame 017240/0865 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2005
From: AGRAWAL, SUDHIR; KANDIMALLA, EKAMBAR; YU, DONG
To: IDERA PHARMACEUTICALS, INC.
Reel/Frame 017188/0410 →